 |
Dear Valued Readers,
June 23rd is all about the Britain Exit or Stay vote. Will they leave the European Union? The latest polls are so close. Currency brokers have dropped all the leverage on the British Pound pairs. Usually you can get 400:1 with non-US brokerages, and they dropped it to 50:1 leverage until the vote is over. They are expecting high volatility. Smart traders are standing aside till it is all over. I'm done trading currency/commodities till next week I hope. Discipline!
I'm going to revisit a dividend paying company that I featured on June 17th, 2014. At the time it was trading $7.06CA and yesterday it closed at $6.53CA. After I reviewed it it topped at $7.48 which wasn't that great but because it pays dividends, you get paid while you wait. If you thought it was a good buy at $7 then a skilled trader would of loved it at $4.50 at the beginning of 2016!
Do you buy your whole position at one time? Or do you wait for market corrections? Do you average down? Average Up? Evaluating fundamentals vs the general market condition. When the markets bleed, you need to reevaluate your portfolio and ask yourself if anything has changed in the company. More info on what is happening with the company below in the blue section, left column.
In the blue-right column below I have included information from our featured company's last news release. The company is making headway into testing and hopefully providing utility companies with their technology. Unlike other start up companies, this company has a product, a finished product! If the testing goes as planned, the next step is..... actual sales! Will the stock remain under .10CA?
You are NOT on the Platinum list unless you see Platinum under the year 2016 in the header. Platinum members get the newsletter first. Subscribe to Platinum with a Deliverable Address
Remember, I'm an investor/trader like you. This is not investment advice, these are my opinions. Please consult your advisor before buyin or selling anything.
Thank You!
- MT-News
|
|
Our Featured Sponsor:
Get all the details before more great news comes out! Click the link below and Good Luck in the Amazon Draw!
From the news last week:
The company is pleased to announce that they have entered into a letter agreement with Tri-State Generation and Transmission Association, Inc. ("Tri-State"), for testing its Dynamic Thermal Circuit Rating (DTCR) technology. Under the agreement, Tri-State will install The Company's temperature monitoring sensor on a Tri-State-owned energized line in Colorado for a period of one year.
The Company's patented, wireless monitoring system supports the use of Dynamic Thermal Circuit Rating (DTCR) technology on congested and remotely-located high-voltage power lines operated by electric utilities. The system provides real-time temperature data and other vital information to utilities that helps them save money on maintenance and maximize the capacity of their transmission systems. Through the use of DTCR technology, transmission capacity can be increased by up to 30% with corresponding increases in revenue to the utility. The sensors are extremely durable, do not require a power source and are easy to install on live (energized) power lines.
Tri-State is a not-for-profit wholesale power supplier to 44 member electric distribution cooperatives and public power districts that collectively serve 1.5 million consumers across 200,000 square miles of service territory in Colorado, Nebraska, New Mexico and Wyoming.
Suresh Singh, President of the company commented, "Working with Tri-State is a wonderful opportunity for the company to optimize our power line monitoring system as we begin to commercialize our technology." The CEO of The Company commented, "The first installation of our high voltage dynamic rating system technology in Colorado is a tremendous milestone for the company, many years of technological development and innovation have led to this. The Company is very pleased to be working with Tri-State Generation and Transmission."
Get more information on this company before more news comes out!
UPGRADE:
The Platinum Newsletter List:
[ Subscribe to Platinum
with a Deliverable Address ]
|
Student Transportation
(STB-TSX/NYSE MKT) |
Founded in 1997, STUDENT TRANSPORTATION INC. (STI) is North America’s most trusted provider of student transportation solutions, operating 13,000 vehicles. STI’s family of local companies delivers safe, reliable and cost-effective transportation, management, logistics and technology solutions to a wide range of customers throughout the U.S. and Canada. Services are delivered by drivers, dispatchers, maintenance technicians, terminal managers, information technology professionals and others, who are caring members of their local communities.
STB is currently paying out a dividend of 8.64% and has about 91.8M shares out. Market cap is about $600M Canadian.
The company has been paying a dividend since 2005.
What I like about it is, kids need to go to school, and I don't think buses will be phased out. Its a pretty recession resistant business.
They are the largest independent and highest growth provider of school bus transportation in North America.
From their Facts Sheet:
MILESTONES:
Date of Incorporation May 15, 1997
IPO - Toronto Stock Exchange December 14, 2004
Listed - NASDAQ September 6, 2011
Symbol (TSX & NASDAQ) STB
2015 Total Annual Revenue U.S. $554.8
Million Bids Won To Date 100+
Number of School Bus Terminals 140+
Number of Vehicles 13,000
Number of Employees 14,000
Number of School Districts Served 360+
Number of School Bus Contracts 240+
Students Transported Daily 1,000,000
Contract Renewal Rate >95% since inception
Last Three News Releases:
June 20th: Wins $3.5M contract in N.Y.
June 9th:
Wins $1.3M managed service deal in Texas
June 6th:
Signs Contract with Iowa School District
So much information at their web site.
|
|
People who respond will be entered into our draw to be drawn when we have 100 entries!
|
|
People who respond get a 13 page corporate PDF presentation and access to their very informative web site.
|
|
|
|
|
|
|
|
Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer
Nasdaq:NYMX +35%
Study Shows Major Reduction to Cumulative Incidence of Prostate Cancer in Study to 1.3%
HASBROUCK HEIGHTS, N.J., June 22, 2016 -- Nymox Pharmaceutical Corporation (NYMX) announced today results from the Company's 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Company's lead drug fexapotide. Men who received fexapotide showed a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease.
The men in the study received fexapotide or placebo for the treatment of their prostate enlargement (BPH) symptoms. All men were thoroughly evaluated to exclude any prostate cancer prior to qualifying for enrollment in the studies.
|
|
|
Cemtrex Announces Share Repurchase Authorization
NASDAQ: CETX +16%
Marks first share buyback program in the Company’s history
Farmingdale, June 22, 2016 -- Cemtrex Inc. (CETX), a world leading industrial and manufacturing solutions company, announced today that its Board of Directors has approved a new share repurchase authorization for the Company’s common stock, under which the Company may repurchase up to one million of its outstanding shares over the next twelve months, depending on market conditions.
Under the stock repurchase program, Cemtrex may repurchase shares in open-market purchases in accordance with all applicable securities laws and regulations.
|
|
|
Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy
Nasdaq: PSTI +11%
PLX-PAD cells increase regeneration of muscle tissue and reduce inflammation and cell death
Pluristem donated cells for the studies performed in conjunction with ADI- the Association Duchenne Israel
HAIFA, Israel, June 22, 2016 -- Pluristem Therapeutics Inc. (PSTI), (PSTI)/(PLTR), a leading developer of placenta-based cell therapy products, today reported positive data from preclinical studies of its PLX-PAD cells in the treatment of Duchenne muscular dystrophy. The studies were conducted in conjunction with ADI, the Association Duchenne Israel, whose members are parents of children with Duchenne. They are committed to helping to find a cure for Duchenne muscular dystrophy through research, clinical trials, and advocacy.
|
|
|
|
|
|
|
If your not interested in stocks or other financial commentaries then please use our instantaneous removal link in the footer of the newsletter.
|
|
|
|
Please be advised that YOU are responsible for your own actions and you should consult your investment advisor before making any investment decisions.
|
|
|
DISCLAIMER:
Our sponsoring company has paid for an advertising package with Market Trend News Inc. Market Trend News Inc has no stock position in the company being featured. Winner of the draw must reside in North America. |
|
|
|
